Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data

Documenti analoghi

• Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis
  di: Dvora R. Sehtman‐Shachar, et al.
  Pubblicazione: (2024)
• Representation of women in randomized controlled trials of novel antidiabetic drugs: A cohort study
  di: Genya Aharon‐Hananel, et al.
  Pubblicazione: (2024)
• Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
  di: Stephanie Shabanowitz, et al.
  Pubblicazione: (2026)
• Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
  di: Noga C. Minsky, et al.
  Pubblicazione: (2025)
• Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
  di: Kenneth Todd Moore, et al.
  Pubblicazione: (2024)